Mapping U.S. POINTER Cognitive-Slope Gains Onto Predicted Clinical Progression: An External-Cohort Translation Analysis With Exploratory Economic Thresholds
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
U.S. POINTER reported a modest structured-versus-self-guided difference in the annual rate of global cognitive change. However, the clinical and economic implications of this incremental standardized cognitive-slope benefit for delaying progression from cognitively normal status to mild cognitive impairment or dementia remain uncertain.
Objectives
To translate the U.S. POINTER cognitive-slope benefit into clinically interpretable progression outcomes in ADNI, A4, and LEARN, and to summarize scenario-based economic implications in ADNI subgroups.
Design
External-cohort translation analysis using two complementary analytic frameworks: an early-change landmark Cox model targeting Month 24 with a prespecified fallback window and a joint longitudinal–survival model.
Setting
ADNI, A4, and LEARN.
Participants
Cognitively normal participants. Landmark analytic samples included 399 ADNI participants with 61 events, 124 A4 participants with 37 events, and 394 LEARN participants with 45 events. Joint-model samples included 486 ADNI participants with 86 events, 1,064 A4 participants with 410 events, and 505 LEARN participants with 87 events.
Intervention
No multidomain lifestyle intervention was administered in ADNI, A4, or LEARN. ADNI and LEARN were observational longitudinal cohorts, whereas A4 was a randomized solanezumab trial; the present analysis did not estimate solanezumab treatment effects. We evaluated a counterfactual +0.029 SD/year improvement in cohort-specific mPACC slope, corresponding to the structured-versus-self-guided cognitive-slope difference reported in U.S. POINTER.
Measurements
The clinical outcome was sustained progression to mild cognitive impairment or dementia. Main translated measures were hazard ratios (HRs), 5-year risk differences (RDs), number needed to treat (NNT), and restricted mean survival time (RMST) differences. ADNI subgroup economic summaries used incremental 2-year delivery-cost scenarios and prespecified willingness-to-pay thresholds for prevented progression events and MCI-free years.
Results
Landmark analyses yielded small translated effects. For the +0.029 SD/year slope shift, HRs were 0.972 (95% CI, 0.949–0.989) in ADNI, 0.998 (0.989–1.005) in A4, and 0.996 (0.990–1.003) in LEARN, with corresponding 5-year RDs of 0.31 percentage points (95% CI, 0.12–0.57), 0.06 (-0.13 to 0.27), and 0.08 (-0.05 to 0.20). Joint models produced larger effects, with HRs of 0.831 (95% CrI, 0.776–0.879), 0.917 (0.907–0.927), and 0.833 (0.746–0.907), and 5-year RDs of 1.26 percentage points (0.90–1.68), 3.04 (2.65–3.43), and 2.25 (1.24–3.45), respectively. Corresponding NNT values were 79.1, 32.9, and 44.5, and RMST gains were 0.297, 1.242, and 0.617 months. In exploratory ADNI subgroup analyses, the small joint-model APOE -ε4+ & Aβ+ subgroup (61 participants, 22 events) showed the largest translated clinical effect, with HR 0.775 (95% CrI, 0.597–0.919), RD 2.65 percentage points (0.93–4.82), NNT 37.7, and RMST gain 0.723 months. In an exploratory threshold exercise, assuming an incremental 2-year delivery cost of $400 per participant for a structured intervention relative to a self-guided/reference intervention and a willingness-to-pay threshold of $100,000 per prevented progression event, the largest threshold-based net monetary benefit was observed in the APOE -ε4+ & Aβ+ joint-model subgroup (+$2,250/person). On an MCI-free-year basis under the same incremental-cost assumption, this subgroup also had the largest threshold-based net monetary benefit (+$5,622/person). These values should be interpreted as scenario-dependent thresholds rather than empirical cost-effectiveness estimates.
Conclusions
A U.S. POINTER–referenced structured-versus-self-guided cognitive-slope increment translated into directionally consistent reductions in predicted progression risk across ADNI, A4, and LEARN. The absolute clinical delay was generally modest and varied with cohort risk structure, biomarker/genotype enrichment, and analytic framework. Exploratory economic-threshold results suggested more favorable margins in higher-risk ADNI subgroups under low incremental-cost and high willingness-to-pay assumptions, but these findings should be interpreted as hypothesis-generating translation estimates rather than empirical cost-effectiveness evidence.
